DGAP-News: amp biosimilars AG / Key word(s): Conference

2015-11-02 / 10:00


amp biosimilars AG to present at German Equity Forum 2015

Hamburg, Germany, November 2, 2015 – amp biosimilars AG (ISIN: DE000A0SMU87), a company specializing in the development of high-quality biosimilars, today announced that it will be presenting for the first time at German Equity Forum being held 23 – 25 November 2015 in Frankfurt am Main, Germany.

Dr. Marc W. Hentz, Chief Executive Officer, and Gunnar Janssen, Chief Financial Officer of amp biosimilars AG, will present at the conference on Monday, 23 November, in the Oslo room at
5.30 p.m. CET.

The German Equity Forum is Europe’s largest and most important capital market event for corporate finance and a central matching platform for senior company representatives from various industries and the financial community. It will take place from Monday to Wednesday, 23 to 25 November 2015, at the Sheraton Frankfurt Airport Hotel and Conference Center in Frankfurt. For more information about the event program, time frame and location, please see the event website, www.eigenkapitalforum.com.

If you want to schedule an investor or a media meeting with amp biosimilars at this event, please e-mail us at: linja.osann@mc-services.eu.

About amp biosimilars AG:
amp biosimilars AG develops high quality biosimilars to meet growing demand on global therapeutic markets and is one of the most innovative and dynamic biosimilar companies in Europe. The company is headquartered in Hamburg and run by a team of leading industry experts. The development of a wide variety of biosimilars will provide patients around the world with access to life-improving and life-saving therapies. The combination of a research platform with state-of-the-art analytics, process technology and clinical expertise as well as regulatory know-how, makes amp biosimilars AG one of the leading companies for biosimilar development and marketing. Thanks to an international network of leading pharmaceutical companies, amp biosimilars AG also has direct access to the strongest growing markets in the world. With this approach amp biosimilars AG has a key position in one of the fastest growing life science markets in the near future. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015. For more information please go to www.ampbiosimilars.com.

Contact:
MC Services AG
Anne Hennecke
T +49 211 529252-22
Email: anne.hennecke@mc-services.eu


2015-11-02 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


407223  2015-11-02 
Disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice. This release and the information contained herein are not for distribution, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.